公开(公告)号：US20240343823A1

公开(公告)日：2024-10-17

申请号：US18432750

申请日：2024-02-05

申请人： Ablynx N.V. ,  Sanofi

发明人： Daniel Janssen ,  Carlo Boutton ,  Evelyne Dombrecht ,  Bram Laukens ,  Paolo Meoni ,  Lily Pao ,  Jan Pype ,  Peter Schotte ,  Benedikte Serruys ,  Ana Paula Vintem ,  Diane Van Hoorick

IPC分类号： C07K16/30 ,  A61K39/00 ,  A61P35/00 ,  C07K16/28

CPC分类号： C07K16/303 ,  A61P35/00 ,  C07K16/2809 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2319/30

摘要： The present technology aims at providing a novel type of drug for treating a subject suffering from cancer. Specifically, the technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that one ISVD binds to TCR and at least two ISVDs bind to GPC3. The present technology also provides nucleic acids, vectors and compositions.

公开(公告)号：US20240317855A1

公开(公告)日：2024-09-26

申请号：US18593621

申请日：2024-03-01

申请人： EUREKA THERAPEUTICS, INC.

发明人： Hong LIU ,  Pengbo ZHANG ,  Lucas HORAN ,  Yiyang XU ,  Binnaz K. STALEY ,  Lianxing LIU ,  Hongruo YUN

IPC分类号： C07K16/28 ,  A61K35/17 ,  A61K38/00 ,  A61K39/00 ,  A61P35/00 ,  C07K14/705 ,  C07K14/725 ,  C07K16/30

CPC分类号： C07K16/2803 ,  A61K35/17 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70521 ,  C07K14/70578 ,  C07K16/2809 ,  C07K16/2827 ,  C07K16/283 ,  C07K16/2833 ,  C07K16/2887 ,  C07K16/303 ,  A61K38/00 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/522 ,  C07K2317/53 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/33

摘要： The present application provides immune cells (such as T cells) comprising a chimeric antibody-T cell receptor (TCR) construct (caTCR) and a chimeric signaling receptor (CSR) construct. The caTCR comprises an antigen-binding module that specifically binds to a target antigen and a T cell receptor module (TCRM) capable of recruiting at least one TCR-associated signaling molecule, and the CSR comprises a ligand-binding domain that specifically binds to a target ligand and a co-stimulatory signaling domain capable of providing a stimulatory signal to the immune cell. Also provided are methods of making and using these cells.

公开(公告)号：US20240316201A1

公开(公告)日：2024-09-26

申请号：US18276703

申请日：2022-02-25

申请人： NANJING LEGEND BIOTECH CO., LTD.

发明人： Xiaohu Fan ,  Jie Mao ,  Qiuchuan ZHUANG ,  Changjiang Zhang

IPC分类号： A61K39/00 ,  A61P35/00 ,  C07K14/52 ,  C07K14/54 ,  C07K14/705 ,  C07K14/725 ,  C07K16/30 ,  C12N5/0783 ,  C12N15/86

CPC分类号： A61K39/464474 ,  A61K39/4611 ,  A61K39/4631 ,  A61P35/00 ,  C07K14/52 ,  C07K14/5434 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70578 ,  C07K16/303 ,  C12N5/0636 ,  C12N15/86 ,  C07K2317/622 ,  C07K2319/03 ,  C07K2319/30 ,  C12N2740/15043

摘要： An immune effector cell expressing an exogenously introduced p40 subunit of IL-12; an exogenously introduced ligand of CCR7 (such as CCL-19 and CCL-21); and a functional exogenous receptor (such as a chimeric antigen receptor) comprising an extracellular antigen binding domain, a transmembrane domain, and an intracellular signaling domain.

公开(公告)号：US20240301085A1

公开(公告)日：2024-09-12

申请号：US18275901

申请日：2022-02-09

申请人： SIMCERE ZAIMING PHARMACEUTICAL CO., LTD.

发明人： Hu GE ,  Shumei YOU

IPC分类号： C07K16/30 ,  A61K39/00 ,  G01N33/68

CPC分类号： C07K16/303 ,  A61K39/4631 ,  G01N33/6854 ,  A61K2039/505 ,  A61K2239/13 ,  A61K2239/21 ,  A61K2239/22 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/92

摘要： Provided is a humanized antibody or antigen-binding fragment that specifically binds to GPC3. The antibody or antigen-binding fragment has high affinity with GPC3 protein, and can be used in the preparation of drugs for treating tumors and the like. Also provided are a nucleic acid molecule encoding the humanized GPC3 antibody or antigen-binding fragment, an expression vector, a host cell, and a method for preparing the antibody or antigen-binding fragment. Also provided are an immunoconjugate comprising same, a chimeric antigen receptor, an immunocompetent cell, a multispecific molecule, and a pharmaceutical composition. Also provided are a method for detecting GPC3, and a method for treating various GPC3-related disorders including hepatocellular carcinoma.

公开(公告)号：US20240294672A1

公开(公告)日：2024-09-05

申请号：US18590651

申请日：2024-02-28

申请人： Chugai Seiyaku Kabushiki Kaisha

发明人： Junichi Nezu ,  Takahiro Ishiguro ,  Atsushi Narita ,  Akihisa Sakamoto ,  Yumiko Kawai ,  Tomoyuki Igawa ,  Taichi Kuramochi

IPC分类号： C07K16/46 ,  A61K39/00 ,  C07K16/28 ,  C07K16/30

CPC分类号： C07K16/46 ,  C07K16/2809 ,  C07K16/2863 ,  C07K16/30 ,  C07K16/303 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/60 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2317/71 ,  C07K2317/73 ,  C07K2317/94 ,  C07K2319/00 ,  C07K2319/30

摘要： Disclosed are bispecific antibodies with heavy chain constant regions having the sequence of an IgG1 constant region with one or more mutations including one or more substitutions that reduce the ability of the heavy chain constant regions to bind to a human Fcγ receptor.

公开(公告)号：US20240294662A1

公开(公告)日：2024-09-05

申请号：US18647183

申请日：2024-04-26

申请人： Novartis AG ,  The Trustees of the University of Pennsylvania

发明人： Gregory Beatty ,  Boris Engels ,  Neeraja Idamakanti ,  Carl H. June ,  Andreas Loew ,  Huijuan Song ,  Qilong Wu

IPC分类号： C07K16/30 ,  A61K31/436 ,  A61K38/00 ,  A61K38/17 ,  A61K39/00 ,  A61K39/395 ,  A61K48/00 ,  C07K14/705 ,  C07K14/715 ,  C07K14/725 ,  C12N5/0783 ,  C12N15/85 ,  C12N15/86

CPC分类号： C07K16/30 ,  A61K31/436 ,  A61K38/1774 ,  A61K38/1793 ,  A61K39/001168 ,  A61K39/39558 ,  A61K48/0058 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/7151 ,  C07K16/303 ,  C07K16/3061 ,  C07K16/3069 ,  C12N5/0638 ,  C12N15/85 ,  C12N15/86 ,  A61K38/00 ,  A61K2039/505 ,  A61K2039/5158 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/74 ,  C12N2740/15041

摘要： Provided are compositions and methods for treating diseases associated with expression of mesothelin. Also provided are a chimeric antigen receptor (CAR) specific to mesothelin, vectors encoding the same, and recombinant T cells comprising the mesothelin CAR. Further provided are methods of administering a genetically modified T cell expressing a CAR that comprises a mesothelin binding domain.

公开(公告)号：US20240269175A1

公开(公告)日：2024-08-15

申请号：US18174565

申请日：2023-02-24

申请人： CRAGE medical Co., Limited

发明人： Zonghai LI ,  Huiping GAO ,  Peng WANG ,  Hua JIANG ,  Huamao WANG

IPC分类号： A61K35/17 ,  A61K9/00 ,  A61K31/519 ,  A61K31/664 ,  A61K31/7048 ,  A61K31/7076 ,  A61K38/20 ,  A61K48/00 ,  A61P35/00 ,  C07K14/705 ,  C07K14/725 ,  C07K16/30

CPC分类号： A61K35/17 ,  A61K9/0019 ,  A61K31/519 ,  A61K31/664 ,  A61K31/7048 ,  A61K31/7076 ,  A61K38/2013 ,  A61K38/202 ,  A61K38/204 ,  A61K38/2073 ,  A61K48/00 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70517 ,  C07K16/303 ,  A01K2207/12 ,  A01K2227/105 ,  C07K2317/24 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/33 ,  C12N2740/16043

摘要： Disclosed herein are methods of treating a subject exhibiting a solid tumor that expresses Glypican-3 (GPC3). The methods typically utilize g GPC3 chimeric antigen receptor immunoresponsive cells to a subject in need thereof to effect killing of tumor cells.

公开(公告)号：US12030955B2

公开(公告)日：2024-07-09

申请号：US16767085

申请日：2018-11-28

申请人： Chugai Seiyaku Kabushiki Kaisha

发明人： Tomoyuki Igawa ,  Hiroyuki Ishikawa ,  Naoka Hironiwa ,  Tatsuya Kawa

IPC分类号： C07K16/28 ,  C07K16/30 ,  C07K16/32

CPC分类号： C07K16/303 ,  C07K16/2809 ,  C07K16/2866 ,  C07K16/32 ,  C07K2317/31 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/569

摘要： The present invention relates to polypeptides containing an antigen-binding domain and a carrying moiety having an inhibiting domain that inhibits the antigen-binding activity of the antigen-binding domain, and having a longer half-life than that of the antigen-binding domain existing alone; methods for producing and screening for the polypeptides; pharmaceutical compositions containing the polypeptide; methods for producing and screening for a single-domain antibody whose antigen-binding activity is inhibited by its association with particular VL, VH or VHH; and fusion polypeptide libraries including a single-domain antibody whose antigen-binding activity is inhibited by its association with particular VL, VH or VHH.

公开(公告)号：US20240199759A1

公开(公告)日：2024-06-20

申请号：US18285628

申请日：2022-04-05

申请人： CYTOVIA THERAPEUTICS, LLC.

发明人： Jean KADOUCHE ,  Wei LI ,  Daniel TEPER

IPC分类号： C07K16/30 ,  A61K39/00 ,  A61K39/395 ,  A61P35/00 ,  C07K16/28

CPC分类号： C07K16/303 ,  A61K39/3955 ,  A61K39/4613 ,  A61P35/00 ,  C07K16/2803 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31

摘要： This disclosure provides bispecific antibody molecules that specifically bind to NKp46 and Glypican 3 (GPC3). The disclosure further relates to combination therapies comprising the bispecific antibody molecules. The bispecific antibody molecules can be used to treat, prevent and/or diagnose cancer or infectious conditions or disorders associated with cells expressing NKp46 and/or GPC3.

公开(公告)号：US20240173427A1

公开(公告)日：2024-05-30

申请号：US18486335

申请日：2023-10-13

申请人： SEAGEN INC.

发明人： Travis Biechele ,  William Arthur ,  Patrick Burke ,  Lori Westendorf

IPC分类号： A61K47/68 ,  A61K31/454 ,  A61K39/00 ,  A61P35/00 ,  C07K16/30

CPC分类号： A61K47/6859 ,  A61K31/454 ,  A61K47/6803 ,  A61P35/00 ,  C07K16/303 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/92

摘要： The invention provides murine, chimeric, and humanized antibodies that specifically bind to GPC3 and conjugates thereof.